The widespread aging of societies results in the intensification of the development of neurodegenerative diseases associated with advanced age, including Parkinson’s disease. Unfortunately, modern medicine is not able to unequivocally determine the etiopathogenesis of the disease, which is why no causative treatment can be given. According to the current state of knowledge, in the course of Parkinson’s disease the substantia nigra pars compacta in the midbrain degenerates, leading to a decrease in dopamine levels in the patient’s brain. This results in neurotransmission disturbances and the development of undesirable effects. Neurodegenerative changes are supposedly caused by the combination of various factors, including genetic factors, chronic inflammation, the interaction of toxins, disturbances in protein metabolism, and oxidative stress. The therapeutic possibilities
associated with the administration of antioxidants, which could alleviate increased oxidative stress
and contribute to the better quality of life of the patient, are considered. Taking into account the
studies on numerous antioxidants, such as coenzyme Q10, B vitamins, vitamin D, vitamin E and
resveratrol, it cannot be unequivocally stated that this is an effective treatment, because experiments
carried out on both humans and animals gave conflicting results. It is reasonable to say that
antioxidant deficiencies should be avoided and the physiological levels should be sought, as this
may be translated into significant health benefits.